Press release
Investigation announced for Investors who lost money with shares of Morphic Holding, Inc. (NASDAQ: MORF)
An investigation for investors in Morphic Holding, Inc. (NASDAQ: MORF) shares over potential securities laws violations.
Investors who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Morphic Holding, Inc. (NASDAQ: MORF) concerning whether a series of statements by Morphic Holding, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Waltham, MA based Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Morphic Holding, Inc. reported that its annual Total Revenue rose from $19.79 million in 2021 to $70.8 million in 2022 and that its Net Loss declined from $95.54 million in 2021 to $59.04 million in 2022.
On September 22, 2023, the Company released abstract data from its EMERALD-1 Phase 2a trial for its drug candidate, MORF-057. Following this news, the price of the Company's stock dropped.
Shares of Morphic Holding, Inc. (NASDAQ: MORF) declined from $63.08 per share on June 12, 2023, to as low as $19.96 per share on October 25, 2023.
Those who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Morphic Holding, Inc. (NASDAQ: MORF) here
News-ID: 3263555 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for Morphic
Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment Report 2024
DelveInsight's, "Primary Sclerosing Cholangitis Pipeline Insight 2024" report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Primary Sclerosing Cholangitis…
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion - …
Eli Lilly and Company (LLY) on July 8, 2024, entered a definitive merger agreement to acquire Morphic Holding, Inc. (MORF) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.
Eli Lilly and Company (NYSE: LLY [https://www.insidearbitrage.com/symbol-metrics/LLY/?utm_source=ABNewswire&utm_medium=PaidPr&utm_campaign=Lilly-Morphic]), a global leader in the pharmaceutical industry, on July 8, 2024, announced the completion of a definitive agreement to acquire Morphic Therapeutic, Inc. (NASDAQ:…
Investigation announced for Investors in Morphic Holding, Inc. (NASDAQ: MORF) ov …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Morphic Holding, Inc.
Investors who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Morphic Holding, Inc officers and directors breached their fiduciary duties and caused damage to the company and…
Primary Sclerosing Cholangitis Pipeline Analysis (2023) Covering Clinical Trials …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Primary Sclerosing Cholangitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Primary Sclerosing Cholangitis Pipeline Insight,…
Global Integrin Beta 1 Market Growth, Trends and Forecast 2021 to 2027 - Avipero …
Global Integrin Beta 1 Market Research Report 2021-2027 is the latest research study published by Market Research Place that aims to gather, record, and analyze the data for the concerns linked to the marketing of goods and services and thereby serve the global industry with an excellent market research report. The report identifies industry trends, determines brand awareness and influence, provides industry insights, and offers competitive intelligence. This report carries…
Integrin Alpha 4 - Pipeline Review, H1 2020 | AxeroVision, Biogen, C4X Discovery …
A new business intelligence report released by HTF MI with title "Integrin Alpha 4 - Pipeline Review, H1 2020" is designed covering micro level of analysis by manufacturers and key business segments. The Integrin Alpha 4 - Pipeline Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative…
